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ABSTRACT 
Thalidomide has demonstrated clinical activity in various malignancies affecting 
immunomodulatory and angiogenesis pathways. The development of novel thalidomide 
analogs with improved efficacy and decreased toxicity is an ongoing research effort. We 
recently designed and synthesized a new class of compounds, consisting of both 
tetrafluorinated thalidomide analogs (Gu973 and Gu998) and tetrafluorobenzamides 
(Gu1029 and Gu992). In this study, we demonstrate the anti-angiogenic properties of 
these newly synthesized compounds. We examined the specific anti-angiogenic 
characteristics in vitro using rat aortic rings with carboxyamidotriazole as a positive 
control. Additionally, further in vitro efficacy was evaluated using HUVECs and PC3 
cells treated with 5μM and 10μM doses of each compound. All compounds were seen to 
reduce microvessel outgrowth in rat aortic rings as well as inhibit HUVECs to a greater 
extent, at lower concentrations than previously tested thalidomide analogs. The anti-
angiogenic properties of the compounds was also examined in vivo in fli1:EGFP 
zebrafish embryos, where all compounds were seen to inhibit the extent of outgrowth of 
newly developing blood vessels. In addition, Gu1029 and Gu973 reduced the anti-
inflammatory response in mpo:GFP zebrafish embryos, while Gu998 and Gu992 showed 
no difference. The compounds anti-tumor effects were also explored in vivo using the 
human prostate cancer PC3 xenograft model. All four compounds were also screened in 
vivo in chicken embryos to investigate their teratogenic potential. This study establishes 
these novel thalidomide analogs as a promising immunomodulatory class with anti-
cancer effects that warrant further development to characterize their mechanisms of 
action. 
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INTRODUCTION  
When thalidomide was originally made available in the 1950s, it was used as a 
non-addictive, non-barbiturate sedative and soon after as an anti-emetic, alleviating the 
symptoms of morning sickness in pregnant women. Shortly thereafter, it was found that 
thalidomide had adverse effects upon fetal development, leading to multiple severe 
deformities in newborns, including phocomelia (shortening of the long bones of the 
limbs), as well as causing miscarriages (1-3). The mechanism for these teratogenic effects 
has since been linked to thalidomide having anti-angiogenic characteristics (4, 5). 
Thalidomide was removed from the market in late 1961 and never received FDA 
approval in the US for the purpose of treating morning sickness. However, interest in 
thalidomide has resurfaced over the past two decades as the drug possesses potent anti-
inflammatory and anti-angiogenic properties.  
Thalidomide is currently FDA approved for the treatment of erythema nodosum 
leprosum (6, 7) and multiple myeloma (8-15). Furthermore, thalidomide has shown some 
activity in acute myeloid leukemia (16), metastatic renal cell carcinoma (17), high-grade 
gliomas (18), prostate cancer (19, 20) and Kaposi’s sarcoma (21). Recent studies have 
also shown the efficacy of two thalidomide analogs, lenalidomide and pomalidomide, for 
the treatment of select malignancies (22). When compared to thalidomide, these 
compounds show increased response rates and less toxicity, however, patients still suffer 
from related side effects, and eventually many will develop resistance to these drugs (23, 
24). The development of novel thalidomide analogs that are safer, and with improved 
activity has been an ongoing research effort. A previous collaboration between the 
National Cancer Institute and the Gütschow lab in Germany, led to the synthesis of 118 
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N-substituted and tetrafluorinated thalidomide analogs, where seven of these compounds 
(four N-substituted and three tetrafluorinated) displayed anti-angiogenic activity when 
tested in vitro and one also displayed anti-angiogenic activity in vivo in chicken and 
zebrafish embryos (5, 25). These analogs were found to be active at much lower 
concentrations than thalidomide. Based on these results, a novel collection of 
tetrafluorinated compounds has been synthesized, comprised of both tetrafluorinated 
thalidomide analogs and tetrafluorobenzamides. The structure of these analogs is based 
upon 5’-OH-thalidomide, a biologically active hydroxylated metabolite of thalidomide, 
which has been shown to have anti-angiogenic activity in vitro (25, 26). We screened this 
library of novel compounds with in vitro and in vivo assays to determine their anti-
angiogenic and anti-inflammatory effects, evaluated their in vivo anti-tumor effects in the 
prostate cancer xenograft model and studied effects on teratogenesis in the chicken 
embryo model. The current study has examined the therapeutic potential of the four lead 
tetrafluorinated thalidomide analog compounds consisting of two tetrafluorobenzamides 
(Gu1029 and Gu992) and two tetrafluorinated thalidomide derivatives (Gu973 and 
Gu998).  
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METHODS 
Thalidomide Analogs 
 Analogs were synthesized by Dr. Agnieszka Ambrozak in the group of Dr. 
Michael Gütschow at the University of Bonn, Germany. US patents of these analogs 
have been filed (Patent No. US 8,143,252 B2, Mar. 27, 2012). Their chemical structures 
are shown in Figure 1. 
Cell lines and reagents 
 Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich (St. Louis, MO). 
All water used was ultra filtered by a MilliQ system (MilliPore, Billerica, MA).  Human 
umbilical vein endothelial cells (HUVEC; Clonetics) were purchased from Lonza 
(Allendale, NJ).  PC3 cells were purchased from American Type Culture Collection 
(Manassas, VA).  
 
Rat Aortic Ring Assay 
 A rat aortic ring assay was performed to determine the extent of the anti-
angiogenicity of the four lead compounds based on previous similar assays (5, 25, 26).  
Briefly, 12-well tissue culture plates were covered with 250 μL Matrigel (Becton-
Dickinson, Bedford, MA) and allowed to gel for 30-45 min at 37 °C and 5% CO2.  
Sections of thoracic aorta were removed from 8- to 10-week old male Sprague Dawley 
rats.  Following excision of fibroadipose tissue, the aortic sections were cut into 1 mm-
long cross sections, placed on Matrigel-coated wells, and layered with an additional 250 
µL of Matrigel. These were then allowed to set, after which the cross-sectional rings were 
covered with endothelial cell growth media (EGM-II) and incubated under 5% CO2 at 37 
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°C overnight. The EGM-II was comprised of endothelial cell basal medium (EBM-II; 
Lonza, Allendale, NJ), in addition to endothelial cell growth factors.  The culture medium 
was then traded for EBM-II that was supplemented with 2% fetal bovine serum, 0.25 
μg/mL amphotericin B, and 10 μg/mL gentamicin.  The aortic rings were treated daily 
with vehicle (0.5% DMSO), carboxyamidotriazole (CAI; 12 μg/mL; positive control), 
Gu973, Gu992, Gu998, or Gu1029, each at a dose of 50μM, for four days. This was 
replicated four times using aortas from four different rats.  The area of angiogenic 
sprouting, reported in square pixels, was quantified using Adobe Photoshop. Data was 
presented as percent growth based on the negative control (vehicle), which was 
normalized to 100% growth. 
 
Antiangiogenic and anti-inflammatory Zebrafish embryo assays 
 Zebrafish were maintained in an approved aquarium habitat at 28°C and all 
necessary ethical and legal approvals were obtained for embryo work. Sexually mature 
males and females were crossed and the progeny were screened for the expression of 
GFP or EGFP. Chorions were removed at 24 hours post fertilization (hpf) using forceps. 
All screening and imaging was performed using a Nikon SMZ1500 stereo dissecting 
microscope and camera. 
 fli1:EGFP zebrafish (27) were used to assess anti-angiogenic properties of the 
compounds. Embryos were exposed to either a vehicle control at 24 hpf, or a Gu 
compound (5-100 μg/mL) for 24 hours. Embryos were anaesthetized in 0.1% tricaine and 
the length and number of intersegmental vessels were quantified as previously described 
(28).  
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 mpo:GFP zebrafish (29) (also known as Tg(mpo:GFP)114) were used to assess the 
anti-inflammatory properties of the compounds. Adult fish were crossed, embryos were 
obtained and incubated until 72 hpf, whereupon they were sedated in 0.1% tricaine then 
given a small cut in the dorsal third of the tail fin. They were then incubated with a 
vehicle control (0.1% DMSO) or a compound of interest (5-100 μg/mL) in aquarium 
water for 24 h as previously described (28). The number of fluorescent neutrophils 
migrating to the wound site was quantified as described previously (28).   
 
NCI 60 Cell Line Screening 
 Gu973, Gu992, Gu998, and Gu1029 were each tested in the NCI60 cell line 
screen at five different concentrations using previously published and standardized 
methodology (30).  This screen assesses the ability of a compound to inhibit growth in 59 
different human tumor cell lines.  
 
Cell Proliferation Assay 
 The four lead compounds were tested for their ability to inhibit cell proliferation 
in vitro, using a CCK-8 assay.  HUVEC cells and PC3 (prostate cancer cell line) were 
plated in 12-well plates with a density of 30,000 cells/well and allowed to attach 
overnight at 37 °C in 5% CO2. The media was then removed and replaced with media 
containing vehicle (0.5% DMSO), Gu973, Gu992, Gu998, or Gu1029, either at 5 or 
10μM for each compound.   
 
In Vivo Mouse Xenograft Study 
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 The in vivo efficacy of the four lead compounds was determined using a variation 
of a previously described prostate cancer xenograft mouse model (31).  PC3 cells were 
allowed to grow in culture and then injected (~3 million cells) into a mouse flank 
subcutaneously.  Tumors were allowed to grow for 9 days before daily intraperitoneal 
(IP) injections of vehicle (5% DMSO in saline), Gu973 (1.55 mg/kg), Gu992 (2.34 
mg/kg), Gu998 (0.42 mg/kg), or Gu1029 (4 mg/kg) were begun.  These doses were the 
maximum tolerated doses determined in a previous study and based upon drug solubility 
(data not shown).  Treatment lasted for 4 weeks, except for Gu973, which was stopped 
after 3 weeks due to adverse effects.  All animal care was provided in accordance with 
the procedures outlined in the “Guide for Care and Use of Laboratory Animals” (National 
Research Council; 1996; National Academy Press; Washington, DC). The study design 
and protocol were approved by the NCI Animal Care and Use Committee (Bethesda, 
MD). 
 
Chicken Embryo Teratogenicity Analysis  
Fertilized White Leghorn chicken embryos were incubated for 3 days in an 
incubator at 37°C, 5% CO2. The eggs were windowed and embryos staged according to 
the Hamburger-Hamilton (HH) stages of chicken embryo development (33). Embryos at 
HH St 18 (E3) were retained for experimentation as at this stage the embryo is 
undergoing organogenesis and rapid growth. Drug administration was carried out as 
previously described (5, 28).  Briefly, embryonic membranes were removed and the 
compound of interest was applied over the embryo.  After the procedure, the window was 
sealed with tape and returned to the incubator. All embryos were treated with 100 μL of 
10 
dosing solution. Initially, compounds were applied to developing chick embryos at 
varying concentrations 50, 100 and 200 μg/ml (5-20 μg/embryo) in order to establish a 
dose-response relationship. These doses were tested as they are within the ranges of 
previous thalidomide and thalidomide analogs screens (5, 28, 34). Once a dose-response 
relationship had been determined for each compound, the concentrations allowing the 
best survival rates were re-tested in a new cohort of embryos. Gu973, Gu998, Gu1029 
were applied at 10 μg/embryo (concentrations of 258.2 μM, 241.1 μM and 266.5 μM 
respectively) and Gu992 was tested at 20 μg/mL (513.7 μM). The compounds were given 
as a single dose and the development of each embryo was noted at 24 and 48 hours after 
drug application. Developmental defects and the survival of the embryos were recorded 
each day.  
 
Statistical considerations 
 All results were presented as mean ± standard error of the mean (SEM). 
Comparisons were made with one-way analysis of variance (ANOVA), followed by 
Dunnett’s test, with a p < 0.05 as the criterion for statistical significance. Statistical 
analysis was performed using GraphPad Prism. 
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RESULTS  
Effect of Lead Compounds on Rat Aortic Angiogenesis 
 Rat aortic microvessel outgrowth was normalized to 100% based on vehicle 
(0.5% DMSO) control.  All lead compounds, each at 50μM, demonstrated approximately 
90% inhibition of angiogenesis, comparable with CAI (Figure 2).  Gu1029 and Gu973 
attenuated microvessel outgrowth to 9.02% and 6.23% of control, respectively.  Gu992 
and Gu998 were also effective anti-angiogenic compounds, each demonstrating inhibition 
of outgrowth to 10.2% and 6.19% of control, respectively (p < 0.001, n = 5). 
 
In Vitro Cancer Cell Proliferation 
We assessed the anti-cancer capabilities of the compounds in the NCI60 screen, 
as well as the PC3 prostate cancer cell line. In the NCI60 screen, three compounds 
significantly reduced growth at a single dose of 10 μM, and went on to be tested at 5 
different doses. All three compounds had a mean 50% growth inhibition (GI50) of all cell 
lines tested over 5 different doses.  Gu973, Gu992, and Gu998 had mean GI50 values of 
5.12 μM, 36.7 μM, and 2.12μM, respectively.  Gu1029 did not induce significant growth 
inhibition in the initial NCI60 cell screen (at a single dose of 10 μM) and thus testing of 
this compound in the NCI60 cell lines was not continued. 
PC3 cells exhibited a decrease in cell viability with each lead compound. Gu973 
and Gu998 inhibited PC3 proliferation in a dose-dependent manner (Figure 3), where 
Gu973 inhibition decreased to 26.0% and 10.9% of control at 5 and 10 μM, respectively, 
and Gu998 inhibited growth to 31.0% and 9.7% of control at 5 and 10 μM, respectively 
(p < 0.0001, n = 8). However, at 10 μM, Gu1029 and Gu992 demonstrated almost no 
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decrease in proliferation in PC3 cells, at 87.7% and 95.5% of control (p > 0.05 n = 8), 
consistent with the NCI60 cell line testing at 10 μM (Gu1029: 95.2%; Gu992: 93%).  
 
In Vitro Endothelial Cell Proliferation  
We then investigated the compounds’ effect on endothelial cell proliferation by 
using the HUVEC cell line. HUVEC cells showed significant reduction in cell viability 
when treated with each compound (n = 8).  Gu973 and Gu992 both demonstrated dose-
dependent inhibition of HUVEC proliferation at 5μM and 10μM (Figure 3), where Gu973 
reduced proliferation to 27.2% and 9.0% of control, respectively, and Gu992 reduced to 
27.1% and 10.7% of control, respectively.  Gu1029 significantly reduced HUVEC cell 
proliferation by >85% at both 5 μM and 10μM. Gu998 was the most effective of the 
compounds, potently inhibiting HUVEC proliferation by >97% at 5 μM and 10 μM (p < 
0.0001).  
 
Gu compounds exhibit anti-angiogenic activity in Zebrafish embryos  
 Thalidomide exhibits anti-angiogenic properties in vitro (4), in vivo (36) and 
when assessed with in ovo chicken embryo assays (38). Moreover, anti-angiogenic 
analogs of thalidomide cause teratogenic effects by inhibiting the growth of newly 
forming vessels (2, 3, 5). fli1:EGFP zebrafish, which are known to be sensitive to 
teratogens (5, 27, 28), were used to assess the ability of Gu compounds to affect the 
development of the forming vasculature. We used the formation of the inter-somitic 
vessels (ISVs) as markers of vessel outgrowth. At 24 hpf, ISVs are present in the anterior 
of the embryos, forming in the spine of the embryos and are yet to form in the posterior 
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of the embryos. Compared to embryos treated with a vehicle control (0.1% DMSO, 
Figure 4A, F, n = 33), treatment with Gu973 reduced the outgrowth of the ISVs at 1 
μg/mL (p < 0.05, n = 9), 10 μg/mL (p < 0.01, n = 9) and at 20 μg/mL (Figure 4B, F, p < 
0.05, n = 17). Gu992 decreased outgrowth of forming vessels at all concentrations tested 
(Figure 4F, 1 μg/mL, p < 0.001, n = 15; 10 μg/mL, p < 0.001, n = 20; 20 μg/mL, p < 
0.001, n = 11; 50 μg/mL, Figure 4C, p < 0.01, n = 5). Gu998 decreased outgrowth 
(Figure 4F) at 1 μg/mL (p < 0.05, n = 10) and10 μg/mL (Figure 4D, p < 0.05, n = 7). 
Gu1029 decreased outgrowth at all concentrations tested (Figure 4F,1 μg/mL, p < 0.05, n 
= 10; 10 μg/mL, p > 0.05, n = 9; 20 μg/mL, p < 0.001, n = 18; 50 μg/mL, Figure 4E, p < 
0.001, n = 11) however the extent of inhibition was not significant at 10 μg/mL. The 
number of sprouting ISVs was also quantified (Figure 4G). Gu973 decreased vessel 
number, but only significantly at 10 μg/mL (p < 0.01, n = 9) and 20 μg/mL (p < 0.05, n = 
17). Gu992 inhibited sprouting significantly at 50 μg/mL (p < 0.001, n = 5). Gu998 
showed a non-significant decrease in sprouting vessels. Gu1029 was the only compound 
that had no effect on the vessel number.  We found that testing at higher concentrations 
(100 μg/mL) killed all the embryos, possibly due to toxicity, although we could not rule 
out the embryos died due to systemic vessel and circulatory failure.  
 
Gu compounds action upon the inflammatory response in zebrafish embryos 
 Thalidomide exhibits anti-inflammatory actions (1-3) and its analog, 
lenalidomide, is known to be clinically effective in the treatment of multiple myeloma via 
its anti-inflammatory properties (39). We therefore tested the Gu compounds to 
determine if they have an effect on the inflammatory response. We tested the compounds 
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on mpo:GFP  zebrafish embryos, where neutrophils express GFP under the control of the 
myeloperoxidase promoter, and are recruited to the wound site following tissue 
injury/damage which allows the study of the inflammatory response (28, 29). Treatment 
with Gu1029 caused a reduction in neutrophil migration to the wound site in a 
concentration dependent manner (Figure 4H), where the response at 10 μg/mL (n = 13) 
15 μg/mL (n = 8), 20 μg/mL (n = 13), 40 μg/mL (n = 8), 50 μg/mL (n = 9) and 100 
μg/mL (n = 7) were all significant (p < 0.001). Gu973 showed a significant inhibition of 
neutrophil numbers and migration at 2.5 μg/mL (p < 0.01, n = 5) 5 μg/mL (p < 0.05, n = 
5) and 6.25 μg/mL (p < 0.01, n = 8) compared to embryos with a tail fin cut but without a 
drug. Gu992 (5 μg/mL and 10 μg/mL, n = 16 and n = 8 respectively) and Gu998 (5 
μg/mL, n = 10) gave no significant response, and neutrophil behavior was similar to the 
controls.  
 
In Vivo Efficacy of Gu compounds in the prostate cancer xenograft model  
 Finally, the behavior of the compounds in mouse models of cancer was evaluated. 
Mice (n=29) were divided into five groups and treated daily for four weeks with a vehicle 
control or one of the four lead compounds. Before day 21 of the study, no compound was 
observed to have a statistically significant decrease in tumor volume size compared to 
vehicle control (Figure 5). However, from day 21 and continuing through the end of the 
study (day 39), Gu1029 showed statistically significant decreases in tumor volume size 
(compared to vehicle) at each time point (p < 0.05). By day 36 of the study, tumor growth 
inhibition was 48.19% compared to control. Treatment lasted 4 weeks for all compounds 
except Gu973, which was stopped after 3 weeks due to animals experiencing abdominal 
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swelling, with moderate weight loss of approximately 10% of baseline body weight.  The 
weight loss of mice treated with Gu973 was significant but stable over the course of the 
experiment, and supplementation with transgel did not reverse condition.  
 Given there was no statistical response from Gu992 and Gu998, these in vivo 
results indicate Gu1029 is a potent compound at inhibiting prostate tumor growth.   
 
Teratogenicity of lead compounds in the developing chicken embryo  
Screening of these compounds during chicken embryo development was 
conducted to assess their potential for teratogenesis (Figure 6). The results are indicative 
of the concentration at which embryos survived the treatment and exhibited defects.  
After establishing a concentration at which embryos could survive the treatment 
(266.5 μM, 10 μg/embryo), ten embryos were treated with Gu1029, of which eight 
survived the treatment. All embryos at 24 hours had hemorrhaging (Figure 6A). Of the 
eight surviving embryos, three of these had twisted spines and six were developmentally 
delayed. Gu973 administration caused defects at 258.2 μM (10 μg/embryo) where ten 
embryos were treated at this concentration. Two of the eight surviving embryos presented 
with microopthalmia, 5/8 were developmentally delayed and 3/8 embryos exhibited 
hemorrhaging. Gu992 exposure was tested at 513.77 μM (20 μg/embryo) in twelve 
embryos, of which eleven survived the treatment. Three embryos had twisted spines, two 
had growth retardation and one embryo had a limb reduction injury. Gu998 was 
administered over developing chicken embryos at 241.1 μM (10 μg/embryo) in eleven 
embryos, seven of which survived the treatment. Gu998 caused a range of complications 
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including two limb defects, microopthalmia, three embryos with spinal defects and two 
embryos that were underdeveloped.  
Defects were seen following drug exposure in every instance (Figure 6E) and 
every treatment caused hemorrhaging in the bodies and heads of the embryos, as well as 
constriction of the vasculature and necrosis of the chorioallantoic membranes (CAM) 
surrounding the embryos. This data indicates all four compounds are teratogenic to the 
developing embryo yet the severity of the injuries caused varies amongst them.  
 
DISCUSSION 
These results show that the four lead tetrafluorinated thalidomide analogs tested 
demonstrated varying degrees of anti-angiogenic, anti-inflammatory, anti-tumor and 
teratogenic characteristics. Gu973 displayed only moderate efficacy in all assays, as well 
as causing unacceptable abdominal swelling, pain, and weight loss in week 3 of the 
mouse xenograft assay. Gu998 was the most effective compound in the in vitro tests, yet 
it showed no significant tumor volume reduction in the in vivo efficacy study. Gu992 was 
seen to have similar effects as Gu998 in most assays excluding the in vitro cell 
proliferation, where Gu992 demonstrated low potency in the NCI60 cell screen and 
minimal activity in inhibiting PC3 cell proliferation. Gu1029 exhibited anti-tumor effects 
in the prostate xenograft study, significant activity against HUVEC proliferation and in 
anti-angiogenic assays but displayed no potency against cancer cell lines. Previous 
studies have found a number of compounds to also be inactive in the NCI60 screen at the 
concentrations tested, which include thalidomide, lenalidomide, aminolevulinic acid and 
levamisole (41). Because the Gu compounds were not cytotoxic in this screen, but did 
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inhibit proliferation in endothelial cells, the results are indicative of the specificity of the 
anti-angiogenic action of the compounds. However, the lack of response from the NCI60 
screen may also be attributed to the fact that the efficacy of at least some of the drugs 
depends on their effect on the immune system or components of the tumor 
microenvironment (40), which would not be detectable in a cell line screen such as the 
NCI60 (38). 
The anti-angiogenic properties of these compounds compared favorably to 
tetrafluorinated thalidomide analogs previously reported by Ng et al. (31) and Lepper et 
al. (32). Multiple cell types are involved in the formation of the microtubules from the rat 
aortic rings, and the order in which they form the sprouts emulates the succession of 
formation in humans, making this assay an excellent indicator of the effect of drugs on 
angiogenesis (42).  Analyzing microvessel growth in the rat aortic ring assay, all 
compounds performed equally well or better at 50 μM than the previously synthesized N-
substituted class of thalidomide analogs at the same dose. Additionally, each compound 
tested here showed greater HUVEC lattice network inhibition at lower concentrations (5 
μM) than similar thalidomide analogs tested previously at 12.5 μM (25). When 
comparing results from the in vitro PC3 cell proliferation assay, Gu992 and Gu1029 had 
no effect at 10 μM. However, Gu973 and Gu998 at 5 μM were both more effective at 
inhibiting PC3 cells than all previously tested compounds at 12.5 μM (25).   
The tetrafluorinated Gu compounds were designed around the structures of CPS 
thalidomide analogs previously found to be efficacious in prostate cancer xenograft 
models and anti-angiogenic (25, 31). Several studies have shown tetrafluorinated 
compounds to exhibit increased bioactivity compared to non-fluorinated compounds (25). 
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The increased activity of Gu973 and Gu998 in vitro compared to the CPS compounds 
(25) may be due to the combination of additional fluorine substituents as well as a more 
appropriate substituent at the phthalimide nitrogen, i.e. a dialkyl barbituric acid (Figure 
1). It has already been shown that non-fluorinated CPS compounds display less anti-
angiogenic activity than their tetrafluorinated counterparts (25). Compounds Gu1029 and 
Gu992 also possess better anti-angiogenic activity than CPS compounds in vitro, but less 
so than Gu973 and Gu998. Scission of one phthaloyl CN bond of the 
tetrafluorophthalimide structure (Gu973 and Gu998) and the loss of one CO unit would 
likely result in increased degrees of conformational freedom of the tetrafluorobenzamide 
structure (Gu1029 and Gu992). This may be a contributing factor towards explaining a 
reduced bioactivity of the tetrafluorobenzamides in the in vitro assays. Similarly, a 
replacement of the methylene bridge by CO in the phthaloyl ring have been shown to 
increase the potency of thalidomide analogs in vitro. Perhaps retaining this 
structural element of thalidomide is a requirement for improved anti-angiogenic activity; 
structure-activity relationship studies are currently ongoing in our laboratory. Other 
thalidomide analogs reported in the literature have also demonstrated varying degrees of 
antiangiogenic and/or anti-tumor properties, for example, lenalidomide and 
pomalidomide. Thus, it should be noted that structural differences between thalidomide 
analogs and thalidomide itself may affect binding to distinct target protein(s) such as 
cereblon and associated downstream factors hence subsequently modifying their 
mechanisms of action. 
Despite these promising in vitro findings, only Gu1029 performed as well in the 
human prostate cancer xenograft assay as previously tested tetrafluorinated analogs (31). 
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When examined by Ng et al., (31), the three chosen compounds (CPS45, CPS49, CPS11) 
previously synthesized and described demonstrated reductions in tumor size of 51%, 
68%, and 90%, respectively. In the current study, Gu1029 was the only compound that 
significantly inhibited prostate tumor growth. Further studies comparing the actions of 
Gu1029 with previously synthesized CPS compounds would be useful to determine the 
tolerability and in vivo efficacy of these compounds, and may allow for the synthesis of 
new compounds with more potent properties.  
Given the teratogenic nature of thalidomide, the lead compounds in this study 
were tested for any effects upon embryonic development using the chicken embryo assay. 
The chicken embryo is a well-established system to study teratogenesis and the effects of 
drugs upon development (2, 3, 5, 28, 34). Gu998 and Gu992 were shown to be 
teratogenic, causing limb, spinal and head defects as well as causing a high death rate. 
Embryos treated with Gu973 and Gu1029 did not produce limb defects, however 
surviving embryos did show hemorrhaging, growth retardation and necrosis in the 
surrounding CAM as well as twisted spines (Gu1029) and microopthalmia (Gu973) at 
equivalent concentrations as Gu998. Full interpretation of this data would require further 
study in higher species. Additionally, these studies were conducted to assess for the 
potential for teratogenic effects and further testing would be required to establish the 
effects of these compounds at lower concentrations. However, these compounds are 
potent and act outside the activity window of the parent molecule thalidomide in the 
chicken embryo, which needs to be applied much earlier in development to induce 
developmental defects (33). The concentrations of compounds used in our in vitro studies 
are comparable to those used in previous work by other groups (25 36). The 
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concentrations used in the chicken embryo in vivo testing are lower (Gu973, Gu998, 
Gu1029) or equivalent (Gu992) to concentrations previously used to assess the 
teratogenicity of thalidomide, and its analog lenalidomide, at doses that induce maximal 
anti-inflammatory responses in zebrafish embryos and TNFalpha analysis in RAW cells 
(28). The compounds were applied once directly over the body of the embryo, and the 
chicken embryo was left to bathe in the solutions, however how much of the drug is able 
to enter the embryo is unclear. Given that this amount is likely small, but the 
concentrations applied are lower or equivalent to concentrations of thalidomide and 
lenalidomide that induce teratogenesis from previous studies (28, 34), the likelihood of 
these compounds possessing teratogenic abilities is highly probable.  
We also assessed the anti-angiogenic and anti-inflammatory effects of these 
compounds on development of the vasculature in fli1:EGFP and mpo:GFP zebrafish 
embryos. We found that all the compounds reduced the extent of outgrowth of the blood 
vessels, although only Gu992 significantly reduced the number of forming blood vessels. 
Gu973 and Gu1029 had a significant decrease in the number of neutrophils migrating to 
the area of the cut. Gu992 and Gu998 did not, however at high concentrations embryos 
were not able to survive the treatments. This indicates the toxicity of these compounds in 
the zebrafish embryo.  
In summary, this study demonstrated that Gu973, Gu992, Gu998, and Gu1029 
possess significant in vitro anti-angiogenic effects with potential anti-tumor activity. Of 
these compounds, Gu998 proved to be the most effective in the greatest number of 
experimental designs. However, Gu1029 displayed the most potential in the human 
prostate cancer xenograft assay, as well as exhibiting anti-inflammatory properties. Given 
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its potency in both angiogenic and inflammatory assays, Gu1029 appears to be a prime 
candidate molecule for further screening as a potential anti-cancer compound. Studies are 
currently underway to determine the downstream targets and effector molecules of 
Gu1029. Preclinical assays which evaluate the efficacy of Gu1029 in the treatment of 
multiple myeloma would be useful to assess the activity in comparison to the currently 
used analogs lenalidomide and pomalidomide. Future studies on the compound’s in vivo 
efficacy are also warranted, including optimization of dose and schedule, improved 
delivery and formulation, to decipher if Gu structural analogs could be more effective or 
safer versions of thalidomide. 
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Figure legends 
Figure 1. Structures of the tetrafluorobenzamides, Gu1029 and Gu992, and the 
tetrafluorinated thalidomide analogs Gu973 and Gu998. 
 
Figure 2. In vitro screening was conducted in the Rat Aortic Ring (RAR) angiogenesis 
assay following the standard protocol. CAI was used as a positive control and shows little 
to no outgrowth. The Gu compounds were dosed at a concentration of 50μM. In 
comparison to the control outgrowth was inhibited in every instance.  
 
Figure 3. In Vitro testing of Gu compounds. Each compound reduced cell proliferation in 
HUVEC cells at 5μM and 10μM. Compounds Gu1029 and Gu992 were tested in PC3 
cells at 10μM and exhibited no effect, while Gu973 and Gu998 were tested at both 10μM 
and 5μM causing a reduction in cell proliferation.  
 
Figure 4. The effect of Gu compounds on transgenic zebrafish. Vessel length is decreased 
by Gu compounds. After incubation with vehicle control (0.1% DMSO) for 24 hours 
embryos had normal blood vessel outgrowth (Figures A, F). Treatment with Gu973 
reduced the outgrowth at 1 and 10 μg/mL, with a slight increase at 20 μg/mL (Figures B, 
F). Gu992 decreased outgrowth at all concentrations tested (Figures F, C). Gu998 
decreased outgrowth (Figure F) at 1 and 10 μg/mL (Figure D). At higher concentrations 
all embryos were dead. Gu1029 decreased outgrowth at all concentrations tested (Figure 
F) however the extent of inhibition was not significant at 10 μg/mL. The number of 
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sprouting vessels was also quantified (Figure G). Gu1029 was the only compound that 
had no effect on the vessel number. Gu998 showed a non-significant decrease in 
sprouting vessels. Gu973 decreased vessel number, but only significantly at 10 μg/mL. 
Gu992 inhibited sprouting significantly at 50 μg/mL. (Figure H) Gu compounds effects 
upon the inflammatory response in mpo:GFP zebrafish. Compared to control embryos, 
Gu973 & Gu1029 significantly reduce neutrophil cell migration. In contrast Gu992 and 
Gu998 did not affect the inflammatory response at concentrations tested. Scale bar 
represents 100 μm. 
 
Figure 5. In vivo efficacy of Gu compounds. (A) The tumor volume in mice inoculated 
with 3 million PC3 cells (n = 29) was monitored over time. All compounds were 
compared to vehicle (5% DMSO in saline). Significance was determined by both 
Student-t and Mann-Whitney tests, with results being similar in both instances. (B) 
Weight loss of treated mice. Weight loss of Gu973 treated mice was significant but 
stable. Supplementation with transgel did not abrogate the weight loss. Severe weight 
loss after the treatment period was seen in some mice with larger tumors.  
 
Figure 6. Application of Gu compounds at HH St 18 (E2.5) causes developmental defects 
in the chicken embryo. Examples of phenotypical outcomes with application of Gu 
compounds at HH St 18. (A) Application of Gu1029 induces hemorhaging in the embryo 
(black arrow head; A) and necrosis in the CAM in ovo (white arrow head; A) (n = 10/10). 
(B) Gu998 causes hemoragging in the limb of the treated embryo (arrowhead; B) (n = 
2/10). The embryo also shows has growth retardation (n = 5/10). (C) Application of 
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Gu992 causes retardation of limb growth (arrow head; C) (n = 1/12). (D) Gu973 causes 
hemoragging through the body of the embryo (n = 3/10). The limbs in particular are 
affected (arrow head; D). Scale bar represents 1000 μm. (E) Application of compounds 
Gu1029 (n = 10), Gu992 (n = 12), Gu973 (n = 10) and Gu998 (n = 11) induces variable 
defects in the developing chick embryo as well as having adverse effects on the 
vasculature within the CAM, and causing premature embryonic death.  
 
